JP2006524203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524203A5 JP2006524203A5 JP2006505175A JP2006505175A JP2006524203A5 JP 2006524203 A5 JP2006524203 A5 JP 2006524203A5 JP 2006505175 A JP2006505175 A JP 2006505175A JP 2006505175 A JP2006505175 A JP 2006505175A JP 2006524203 A5 JP2006524203 A5 JP 2006524203A5
- Authority
- JP
- Japan
- Prior art keywords
- thrombin
- pharmaceutical composition
- disease
- increase
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000190 Thrombin Proteins 0.000 claims 8
- 229960004072 thrombin Drugs 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000003790 Thrombin receptors Human genes 0.000 claims 6
- 108090000166 Thrombin receptors Proteins 0.000 claims 6
- 206010003178 Arterial thrombosis Diseases 0.000 claims 4
- 206010047249 Venous thrombosis Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical group C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 3
- 229960002768 dipyridamole Drugs 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229960004676 antithrombotic agent Drugs 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 230000007214 atherothrombosis Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000010102 embolization Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 claims 2
- 229950010718 mopidamol Drugs 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- 229960000288 dabigatran etexilate Drugs 0.000 claims 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002137 melagatran Drugs 0.000 claims 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46516803P | 2003-04-24 | 2003-04-24 | |
| PCT/EP2004/004097 WO2004093881A2 (en) | 2003-04-24 | 2004-04-17 | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524203A JP2006524203A (ja) | 2006-10-26 |
| JP2006524203A5 true JP2006524203A5 (cg-RX-API-DMAC10.html) | 2007-06-28 |
Family
ID=33311001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505175A Pending JP2006524203A (ja) | 2003-04-24 | 2004-04-17 | トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
Country Status (12)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| AU2005245271A1 (en) | 2004-05-13 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Use of dipyridamole for treatment of resistance to platelet inhibitors |
| JP2008517974A (ja) * | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| DE102005028168B3 (de) | 2005-06-17 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung |
| CA2657269A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors |
| CA2657270A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
| JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| JP2012500244A (ja) * | 2008-08-19 | 2012-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍療法におけるダビガトラン |
| BRPI0921353A2 (pt) * | 2008-11-11 | 2015-12-29 | Boehringer Ingelheim Int | método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional. |
| WO2011085473A1 (en) * | 2010-01-13 | 2011-07-21 | Linda Penn | Treating cancer with statins and compounds having dipyridamole activity |
| AU2016337564A1 (en) * | 2015-10-15 | 2018-05-31 | Drug Rediscovery Group Ltd | Low dose oral dipyridamole compositions and uses thereof |
| US12606797B2 (en) * | 2018-06-15 | 2026-04-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of detection of mechanically-activated platelet activation and uses thereof |
| US20260060965A1 (en) * | 2024-08-26 | 2026-03-05 | Research Institute at Nationwide Children’s Hospital | Modulating the acute foreign body reaction to reduce stenosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| GB1051218A (cg-RX-API-DMAC10.html) | 1963-03-09 | |||
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
| US20020048599A1 (en) | 2000-10-20 | 2002-04-25 | Thomas H. Mueller | Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
| HUP0304058A2 (hu) * | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
| EP1308179A1 (en) * | 2001-10-30 | 2003-05-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Improved endoprosthetic device |
| US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
| JP2006500365A (ja) * | 2002-08-14 | 2006-01-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ｐ３８ＭＡＰキナーゼインヒビターを用いた抗凝固及び線維素溶解療法 |
| JP2006516593A (ja) * | 2003-02-07 | 2006-07-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
-
2004
- 2004-04-17 WO PCT/EP2004/004097 patent/WO2004093881A2/en not_active Ceased
- 2004-04-17 RU RU2005136383/14A patent/RU2005136383A/ru not_active Application Discontinuation
- 2004-04-17 BR BRPI0409796-3A patent/BRPI0409796A/pt not_active IP Right Cessation
- 2004-04-17 CA CA002523157A patent/CA2523157A1/en not_active Abandoned
- 2004-04-17 MX MXPA05011432A patent/MXPA05011432A/es not_active Application Discontinuation
- 2004-04-17 JP JP2006505175A patent/JP2006524203A/ja active Pending
- 2004-04-17 EP EP04728114A patent/EP1622621A2/en not_active Withdrawn
- 2004-04-17 AU AU2004231306A patent/AU2004231306A1/en not_active Abandoned
- 2004-04-17 EP EP09152218A patent/EP2062580A1/en not_active Withdrawn
- 2004-04-17 KR KR1020057020187A patent/KR20060007034A/ko not_active Withdrawn
- 2004-04-17 CN CNA200480017862XA patent/CN1812792A/zh active Pending
- 2004-04-22 US US10/830,294 patent/US20050014770A1/en not_active Abandoned
-
2005
- 2005-10-04 ZA ZA200508016A patent/ZA200508016B/en unknown
-
2006
- 2006-09-01 US US11/469,503 patent/US20070105753A1/en not_active Abandoned
-
2009
- 2009-04-03 US US12/418,001 patent/US20090192123A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sesler | Stress-related mucosal disease in the intensive care unit: an update on prophylaxis | |
| RU2005136383A (ru) | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов | |
| JP2004525179A5 (cg-RX-API-DMAC10.html) | ||
| AR061996A1 (es) | Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular | |
| JP2003523325A5 (cg-RX-API-DMAC10.html) | ||
| JP2023533464A5 (cg-RX-API-DMAC10.html) | ||
| JP2010526103A5 (cg-RX-API-DMAC10.html) | ||
| JP2008533151A5 (cg-RX-API-DMAC10.html) | ||
| JP2006513202A5 (cg-RX-API-DMAC10.html) | ||
| JP2017529382A5 (cg-RX-API-DMAC10.html) | ||
| RU2009113615A (ru) | Ингибитор киназы | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| KR20160043117A (ko) | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 | |
| CA2921669A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2010143935A (ja) | 血管新生を減少させる方法 | |
| RU2008143703A (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА | |
| Sorbera et al. | Dabigatran/dabigatran etexilate | |
| BRPI0921692A2 (pt) | composto carbamato ou o sal do mesmo | |
| JP2020529995A5 (cg-RX-API-DMAC10.html) | ||
| JP2021006538A (ja) | デルタ肝炎ウイルス感染の治療 | |
| HRP20120754T1 (hr) | Dozirni oblik koji sadrži pantoprazol kao aktivni sastojak | |
| JPWO2013089164A1 (ja) | 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤 | |
| US20080004279A1 (en) | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | |
| JP2008517974A (ja) | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 | |
| Sukenaga et al. | Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities |